natgillin/translations-raw huggingface dataset:
In both placebo-controlled and open-label follow-up clinical trials for rheumatoid arthritis, cases of lupus- like syndrome were reported uncommonly.
U oba placebom kontrolirana klinička istraživanja i u otvorenim kliničkim praćenjima bolesnika s reumatoidnim artritisom rijetko su zabilježeni slučajevi sindroma nalik lupusu.
In both RAISE and TRA100773B the response to eltrombopag relative to placebo was similar irrespective of ITP medicinal product use, splenectomy status and baseline platelet count (≤ 15,000/µl, > 15,000/µl) at randomisation.
U oba ispitivanja - RAISE i TRA100773B, odgovor na eltrombopag u odnosu na placebo je bio sličan, bez obzira na primjenu drugih lijekova za liječenje ITP-a, splenektomiranost bolesnika ili početni broj trombocita (≤ 15 000/µl, > 15 000/µl) na početku randomizacije.
In both schedules, a booster response indicative of immunological priming was observed for each vaccine serotype (Table 7 and Table 8).
U oba rasporeda cijepljenja primijećen je dodatan (booster) odgovor indikativan za adekvatnu primarnu imunizaciju za svaki serotip sadržan u cjepivu (Tablica 7 i Tablica8).
In both schedules, a booster response indicative of immunological priming was observed.
U oba rasporeda primijećen je odgovor na docjepljivanje indikativan za primarnu imunizaciju.
In both studies all patients had received anthracycline.
U oba ispitivanja svi su pacijenti primili antraciklin.
In both studies concurrent use of stable doses of folic acid, oral corticosteroids (≤ 10 mg/day) and/or non-steroidal anti-inflammatory drugs (NSAIDs) was permitted.
U oba je ispitivanja bila dopuštena istodobna primjena ustaljenih doza folne kiseline, peroralnih kortikosteroida (≤ 10 mg na dan) i/ili nesteroidnih protuupalnih lijekova.
In both studies concurrent use of stable doses of folic acid, oral corticosteroids (≤ 10 mg/day) and/or non-steroidal antiinflammatory drugs (NSAIDs) was permitted.
U oba je ispitivanja bila dopuštena istodobna primjena ustaljenih doza folne kiseline, peroralnih kortikosteroida (≤ 10 mg na dan) i/ili nesteroidnih protuupalnih lijekova.
In both studies concurrent use of stable doses of folic acid, oral corticosteroids (≤10 mg/day) and/or non-steroidal anti-inflammatory drugs (NSAIDs) was permitted.
U oba je ispitivanja bila dopuštena istodobna primjena ustaljenih doza folne kiseline, peroralnih kortikosteroida (≤ 10 mg na dan) i/ili nesteroidnih protuupalnih lijekova.
In both studies dexrazoxane treatment prevented the development of necrosis, allowed cancer treatment to continue as scheduled in the majority of patients (70.4 %), and reduced the occurrence of sequelae (only few and mild long-term sequelae were observed).
U oba ispitivanja, kod većine pacijenata (70,4%) liječenje deksrazoksanom spriječilo je razvoj nekroze, omogućilo nastavak planiranog liječenja raka te smanjilo pojavu sekvele (uočeno je samo nekoliko blagih dugotrajnih sekvela).
In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 – 13.7%, (p<0.001).
U oba je ispitivanja esomeprazol u dozi od 20 mg postigao značajno bolje rezultate u usporedbi s placebom u primarnoj mjeri ishoda, potpunom povlačenju žgaravice što se definira kao izostanak epizode žgaravice tijekom posljednjih 7 dana prije završnog posjeta (33,9%- 41,6% u odnosu na 11,9-13,7% kod bolesnika koji su primali placebo, (p<0,001).
In both studies LEVP 2006-1 and LEVP 2006-4, administration of Cinryze resulted in increases in antigenic and functional C1 inhibitor levels post-infusion compared to pre-infusion values, with similar trends observed in children and adults.
U oba ispitivanja LEVP 2006-1 i LEVP 2006-4 primjena lijeka Cinryze dovela je do povišenja razine antigene i funkcionalne aktivnosti inhibitora C1 nakon infuzije u usporedbi s vrijednostima prije infuzije, uz slične trendove opažene u djece i odraslih.
In both studies of the solution for injection, patients receiving Abilify had a greater reduction in symptoms of agitation than those receiving placebo.
U oba ispitivanja otopine za injekcije bolesnici koji primaju Abilify imali su veću redukciju simptoma agitacije od onih koji su primali placebo.
In both studies one third of the patients in average had Sjögren’s syndrome; as for the overall population, a statistically significant improvement in CFS in favour of IKERVIS was observed in this subgroup of patients.
U oba ispitivanja prosječno je jedna trećina bolesnika imala Sjögrenov sindrom; kao i u ukupnoj populaciji, u ovoj podskupini bolesnika uočeno je signifikantno poboljšanje nalaza CFS-a u korist IKERVISA.
In both studies spironolactone use was not allowed as spironolactone binds to the androgen receptor and may increase PSA levels.
U oba ispitivanja primjena spironolaktona nije bila dopuštena, budući da se spironolakton veže na androgene receptore i može povisiti razine PSA.
In both studies the clearance rates were higher after illumination with narrow light spectrum devices but the incidence and intensity of administration site disorders (e.g. transient pain, erythema) increased in patients illuminated with these devices (see tables above and section 4.8).
U oba su ispitivanja stope očišćenosti bile više nakon osvjetljavanja uređajima uskog spektra svjetlosti ali su se incidencija i intenzitet poremećaja na mjestu primjene (npr. prolazna bol, eritem) povećali u bolesnika osvjetljivanih takvim uređajima (vidjeti gornje tablice i dio 4.8).
In both studies the main measure of effectiveness was the number of patients who responded to treatment 6 weeks after the injection as shown by an improvement in symptom scores.
U oba ispitivanja glavna mjera djelotvornosti bio je broj bolesnika koji su odgovorili na terapiju nakon 24 tjedna, što je vidljivo na temelju boljih rezultata simptoma.
In both studies the primary efficacy endpoint was evaluated at 52 weeks.
U obje studije primarna mjera ishoda djelotvornosti ocijenjena je u 52. tjednu.
In both studies the treatment lasted for three months (1 treatment course):
U oba je ispitivanja liječenje trajalo do tri mjeseca (jedna serija liječenja).
In both studies there was a significant improvement in growth rate in the naïve patients, increasing from 4.2 to 10.9 cm/year in one study and from 4.8 to 11.2 cm/year in the other at 12 months.
U oba ispitivanja došlo je do znatnog poboljšanja stope rasta prethodno neliječenih bolesnika s povećanjima od 4,2 do 10,9 cm/godinu i od 4,8 do 11,2 cm/godinu kod drugog ispitivanja u 12. mjesecu.
In both studies there were significant decrease of individual serotypes 6B and 19F. In the nested Finnish study, a significant reduction was also observed for individual serotypes 14, 23F and, in the 3 dose primary schedule, for the cross-reactive serotype 19A.
U oba je ispitivanja primijećeno značajno smanjenje pojedinačnih serotipova 6B i 19F. U ugniježđenom finskom ispitivanju primijećeno je i značajno smanjenje pojedinačnih serotipova 14 i 23F, a kod primarne imunizacije s 3 doze i smanjenje ukriženo reaktivnog serotipa 19A.
In both studies Truvada was compared with placebo (a dummy treatment) in adults at high risk of sexually transmitted HIV-1 infection.
U obama ispitivanjima lijek Truvada uspoređen je s placebom (prividno liječenje) u odraslih osoba izloženih visokom riziku od spolno prenosive infekcije virusom HIV-1.
In both studies, 6 months treatment with Xadago increased the time during the day during which patients were ‘on’ and able to move by 30-60 minutes when compared with placebo.
U oba ispitivanja, 6-mjesečna terapija s lijekom Xadago povećala je vrijeme tijekom dana tijekom kojeg su bolesnici bili "uključeni" i mogli su se kretati 30-60 minuta u usporedbi s placebom.
In both studies, a total of 347 patients were randomized and received OZURDEX and 350 patients received sham.
U oba ispitivanja ukupno 347 bolesnika raspoređeno je metodom slučajnog izbora u skupinu koja je primila OZURDEX, a 350 u skupinu koja je primila placebo.
In both studies, a total of 347 patients were randomized and received OZURDEX and 350 patients received sham.
U oba ispitivanja, ukupno 347 bolesnika raspoređeno je metodom slučajnog izbora u skupinu koja je primila OZURDEX, a 350 u skupinu koja je primila placebo.
In both studies, a total of 67% patient viruses were resistant and 22% were possibly resistant to the pre-selected comparator PIs.
U oba ispitivanja, ukupno 67% bolesnika imalo je rezistentne viruse, a 22% moguće rezistentne na prethodno odabrane kontrolne IP.
In both studies, ambrisentan was added to patients’ supportive/background medication, which could have included a combination of digoxin, anticoagulants, diuretics, oxygen and vasodilators (calcium channel blockers, ACE inhibitors).
U oba ispitivanja ambrisentan je pridodan suportivnim/postojećim lijekovima, koji su mogli uključivati kombinaciju digoksina, antikoagulansa, diuretika, kisika i vazodilatatora (blokatori kalcijskih kanala, ACE inhibitori).
In both studies, changes in exposure (AUC and Cmax) of desloratadine and 3-hydroxydesloratadine were not clinically relevant.
U oba ispitivanja promjene u izloženosti (AUC i Cmax) desloratadinu i 3- hidroksidesloratadinu nisu bile klinički značajne.
In both studies, decreases in HbA1c were evident in both treatment groups as early as the first post-treatment HbA1c measurement (weeks 4 or 6).
U oba ispitivanja smanjenja HbA1c bila su očita u obje liječene skupine već prilikom prvog mjerenja HbA1c nakon primjene liječenja (tjedni 4 ili 6).
In both studies, Duloxetine Lilly 60 mg once daily and 60 mg twice daily significantly reduced pain compared with placebo.
U oba je ispitivanja Duloksetin Lilly u dozi od 60 mg jednom dnevno i 60 mg dva puta dnevno značajno umanjila bol u usporedbi s placebom.
In both studies, Eliquis was compared with enoxaparin (another medicine used to prevent blood clots).
U oba ispitivanja, Eliquis je uspoređen s enoksaparinom (drugim lijekom koji se koristi za sprječavanje krvnih ugrušaka).
In both studies, frequency, type and severity of adverse reactions observed in children and adolescents have been generally consistent with those observed in adults, with the exception of infections which were reported at a higher frequency, especially in children below the age of 3 years.
U oba ispitivanja učestalost, vrsta i težina nuspojava primijećenih u djece i adolescenata u načelu su bile u skladu s onima primijećenim u odraslih bolesnika, uz iznimku infekcija koje su bile zabilježene uz veću učestalost, osobito kod djece mlađe od 3 godine.
In both studies, Genvoya was compared with another antiviral medicine which contained the active ingredients elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil.
Lijek Genvoya u oba je ispitivanja uspoređen s drugim antivirusnim lijekom koji sadrži djelatne tvari elvitegravir, kobicistat, emtricitabin i tenofoviralafenamid.
In both studies, improvements in FEV1 were rapid in onset (day 15) and durable through 48 weeks.
U oba je ispitivanja poboljšanje FEV1 nastupilo brzo (15. dana) i trajalo je 48 tjedana.
In both studies, lung function was improved and the treatment was well tolerated compared to the corresponding dose of budesonide alone.
Plućna funkcija poboljšala se u oba ispitivanja, a liječenje je dobro podnešeno u usporedbi s odgovarajućom dozom budezonida primjenjenog samostalno.
In both studies, more patients had a partial response to Atriance treatment, with blood counts returning towards normal levels.
U oba ispitivanjam više je bolesnika imalo djelomičan odgovor na lijek Atriance, pri čemu se broj krvnih stanica vratio na normalne razine.
In both studies, patients adding Azilect spent an average of around one hour less in the ‘off’ state than those adding placebo.
U obama ispitivanjima bolesnici kojima je dodan lijek Azilect proveli su prosječno jedan sat manje u lošem stanju nego bolesnici koji su primali placebo.
In both studies, patients had advanced terminal illness and limited life expectancy, with the majority having a primary diagnosis of incurable cancer; other primary diagnoses included end-stage COPD/emphysema, cardiovascular disease/heart failure, Alzheimer’s disease/dementia, HIV/AIDS, or other advanced illnesses.
U oba ispitivanja bolesnici su imali uznapredovalu terminalnu bolest s ograničenim očekivanjem trajanja života, a većina je bila s primarnom dijagnozom neizlječivog raka; ostale primarne dijagnoze uključivale su terminalni stadij KOPB/emfizema, kardiovaskularnu bolest/zatajenje srca, Alzheimerovu bolest/demenciju, HIV/AIDS ili druge uznapredovale bolesti.
In both studies, patients in the lenalidomide/dexamethasone (len/dex) group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28- day cycle.
U oba ispitivanju bolesnici liječeni lenalidomidom/deksametazonom (len/deks) uzimali su 25 mg lenalidomida peroralno jednom dnevno od 1. do 21. dana te odgovarajuću kapsulu placeba jednom dnevno od 22. do 28. dana u svakom 28-dnevnom ciklusu.
In both studies, patients taking Rasagiline ratiopharm spent an average of around one hour less in the ‘off’ state than those taking placebo.
U oba ispitivanja, bolesnici koji su uzimali Razagilin ratiopharm proveli su prosječno otprilike jedan sat manje u „isključenom“ stanju u odnosu na one koji su uzimali placebo.
In both studies, patients were randomised to 1 of 4 treatment groups: Thyrogen + 30 mCi 131-I, Thyrogen + 100 mCi 131-I, thyroid hormone withdrawal + 30 mCi 131-I, or thyroid hormone withdrawal + 100 mCi 131-I, and patients were assessed about 8 months later.
U oba su ispitivanja bolesnici randomizirani u 1 od 4 terapijske skupine: Thyrogen + 30 mCi 131-I, Thyrogen + 100 mCi 131-I, prekid terapije tireoidnim hormonom + 30 mCi 131-I ili prekid terapije tireoidnim hormonom + 100 mCi 131-I te su ocijenjeni nakon približno 8 mjeseci.
In both studies, patients were randomized 2:1 to apremilast 30 mg BID or placebo for 16 weeks (placebo-controlled phase) and from Weeks 16-32, all patients received apremilast 30 mg BID (maintenance phase).
U oba ispitivanja bolesnici su bili randomizirani u omjeru 2:1 na apremilast od 30 mg BID ili placebo do 16. tjedna (placebom kontrolirana faza), a od 16. do 32. tjedna svi su bolesnici primali apremilast od 30 mg BID (faza održavanja).
In both studies, patients were randomly assigned in a 1:1:1 ratio to 1 of 3 dosing regimens:
U oba ispitivanja bolesnici su bili nasumično raspodijeljeni u omjeru 1:1:1 na 1 od 3 režima doziranja:
In both studies, plasma progesterone levels for subjects receiving efavirenz and DMPA remained low consistent with suppression of ovulation.
ispitanike koji su primali efavirenz i DMPA ostale niske, sukladno supresiji ovulacije.
In both studies, Revlimid was compared with placebo (a dummy treatment), both taken in combination with dexamethasone.
U oba ispitivanja Revlimid je uspoređen s placebom (prividnim liječenjem), te je u oba slučaja uzet s deksametazonom.
In both studies, subjects received either a two dose schedule of Ambirix or a three dose regimen of the combined vaccine containing 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface antigen.
U oba ispitivanja, ispitanici su primili ili dvije doze cjepiva Ambirix ili režim od tri doze kombiniranog cjepiva koje sadrži 360 ELISA jedinica virusa hepatitisa A inaktiviranog formalinom i 10 mikrograma rekombinantnog površinskog antigena hepatitisa B.
In both studies, the 10 mg/kg dose of Benlysta was more effective than the 1 mg/kg dose.
U oba je ispitivanja doza lijeka Benlysta od 10 mg/kg bila djelotvornija od doze od 1 mg/kg.
In both studies, the baseline demographic and disease-related characteristics were comparable between the lenalidomide/dexamethasone and placebo/dexamethasone groups.
U oba ispitivanja, početne demografske i s bolešću povezane karakteristike bile su usporedive između skupina koje su primale lenalidomid/deksametazon i placebo/deksametazon.
In both studies, the main measure of effectiveness was based on the number of patients who had blood clots forming in the veins or who died of any cause during the treatment period.
U oba ispitivanja glavno mjerilo djelotvornosti temeljilo se na broju bolesnika kod kojih je zabilježeno stvaranje ugrušaka u venama ili koji su preminuli od bilo kojeg uzroka tijekom razdoblja liječenja.
In both studies, the main measure of effectiveness was how Ultibro Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
U oba ispitivanja, glavna mjera djelotvornosti bila je način na koji je Ultibro Breezhaler poboljšao bolesnikove forsirane izdisajne volumene (FEV1, maksimalni volumen zraka koji osoba može izdahnuti u jednoj sekundi) nakon 26 tjedana liječenja.
In both studies, the main measure of effectiveness was how Ulunar Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
U oba ispitivanja, glavna mjera djelotvornosti bila je način na koji je Ulunar Breezhaler poboljšao bolesnikove forsirane izdisajne volumene (FEV1, maksimalni volumen zraka koji osoba može izdahnuti u jednoj sekundi) nakon 26 tjedana liječenja.
In both studies, the main measure of effectiveness was how Xoterna Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 26 weeks of treatment.
U oba ispitivanja, glavna mjera djelotvornosti bila je način na koji je Xoterna Breezhaler poboljšao bolesnikove forsirane izdisajne volumene (FEV1, maksimalni volumen zraka koji osoba može izdahnuti u jednoj sekundi) nakon 26 tjedana liječenja.
In both studies, the main measure of effectiveness was the decline in the functioning of the patients’ lungs over the course of 1 year of treatment, measured by their forced vital capacity (FVC).
U oba ispitivanja, glavna mjera djelotvornosti bilo je smanjenje u funkciji pluća bolesnika tijekom razdoblja 1 godine liječenja, izmjereno njihovim forsiranim vitalnim kapacitetom (FVC).
In both studies, the main measure of effectiveness was the number of patients who had a lasting response to treatment.
U oba ispitivanja glavno mjerilo djelotvornosti bio je broj bolesnika s dugotrajnim pozitivnim rezultatom liječenja.
In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.
Glavno mjerilo djelotvornosti u oba ispitivanja bio je broj bolesnika čiji rezultati krvnih pretraga šest mjeseci nakon završetka liječenja nisu pokazivali znakove virusa hepatitisa C.
In both studies, the main measure of effectiveness was the number of patients whose disease activity decreased to a certain level after 12 months.
U oba ispitivanja glavna mjera djelotvornosti bio je broj bolesnika u kojih se aktivnost bolesti smanjila na određenu razinu nakon 12 mjeseci.
In both studies, the main measure of effectiveness was the proportion of patients who responded to treatment, i.e. whose GH and IGF-1 levels decreased to pre-defined values (less than 2.5 micrograms/liter for GH or within normal limits for IGF-1).
U oba ispitivanja, glavna mjera djelotvornosti bio je udio bolesnika koji su odgovorili na liječenje, odnosno čije su se koncentracije HR i IGF-1 smanjile na prethodno definirane vrijednosti (manje od 2,5 mikrograma/litri za HR ili unutar normalnih ograničenja za IGF-1).
In both studies, the mean percent improvement in PASI from baseline remained stable during the Randomized Treatment Withdrawal Phase for patients re-randomized to apremilast at Week 32 (Table 5).
U oba ispitivanja, srednja vrijednost postotka poboljšanja u rezultatu PASI u odnosu na početnu vrijednost ostala je stabilna tijekom faze obustave randomiziranog liječenja u bolesnika koji su ponovno randomizirani na apremilast u 32. tjednu (tablica 5).
In both studies, the patients were treated with Atriance, but its effects were not compared with those of any other medicine.
U oba ispitivanja, bolesnici su liječeni lijekom Atriance, no njegovo djelovanje nije uspoređeno s onim bilo kojeg drugog lijeka.
In both studies, the primary efficacy endpoint was the mean change from baseline in BCVA at Week 52 and both Eylea 2Q8 and Eylea 2Q4 groups demonstrated statistical significance and were superior to the control group.
U oba je ispitivanja primarni ishod djelotvornosti bio srednja vrijednost promjene BCVA u odnosu na početnu vrijednost mjereno u 52. tjednu i obje skupine, Eylea primijenjena u dozi od 2 mg svakih
In both studies, the primary endpoint was the proportion of patients who achieved PASI-75 at Week 16.
U oba ispitivanja primarni ishod bio je udio bolesnika koji su postigli PASI-75 u 16. tjednu.
In both studies, treatment with epoetin theta resulted in a significant haemoglobin response (p < 0.001), defined as an increase in haemoglobin of ≥ 2 g/dl without transfusion, and a significant reduction in transfusion requirements (p < 0.05) in comparison to placebo.
U oba ispitivanja, liječenje epoetinom theta dovelo je do značajnog hemoglobinskog odgovora (p < 0,001) koji se definira kao porast hemoglobina od ≥ 2 g/dl bez transfuzije te do značajnog smanjenja potreba za transfuzijom (p < 0,05) u odnosu na skupinu koja je primala placebo.
In both studies, which were still ongoing at the time of Tagrisso’s initial evaluation, the medicine was not compared with any other treatment.
U oba ispitivanja, koja su još uvijek bila u tijeku u trenutku ocjene lijeka Tagrisso, lijek nije uspoređen ni s jednom drugom terapijom.
In both studies, which were still ongoing at the time of Zykadia’s evaluation, the medicine was not compared with any other treatment.
U oba ispitivanja, koja su još uvijek bila u tijeku u trenutku ocjene lijeka Zykadia, lijek nije uspoređen niti s jednom drugom terapijom.
In both Study 1 and Study 2, patients randomised to receive placebo who were non-responders at Week 12 then crossed over to receive Cosentyx (either 150 mg or 300 mg) at Weeks 12, 13, 14, and 15, followed by the same dose every month starting at Week 16.
I u prvom i u drugom ispitivanju bolesnici randomizirani na primanje placeba koji nisu imali odgovor u 12. tjednu su prešli u skupinu koja je primala Cosentyx (ili 150 mg ili 300 mg) u 12., 13., 14. i 15. tjednu, nakon čega je slijedila ista doza svakoga mjeseca počevši od 16. tjedna.
In both Study 3 and Study 4, patients randomised to Cosentyx received 150 mg or 300 mg doses at Weeks 0, 1, 2, and 3, followed by the same dose every month starting at Week 4.
I u trećem i u četvrtom ispitivanju bolesnici randomizirani na Cosentyx primali su doze od 150 mg ili 300 mg u 0., 1., 2. i 3. tjednu, nakon čega je slijedila ista doza svakog mjeseca počevši od 4. tjedna.
In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range ( 2.0).
U oba ispitivanja Einstein DVT i Einstein PE, režim komparativnog liječenja sadržavao je enoksaparin primjenjivan najmanje 5 dana u kombinaciji s liječenjem antagonistom vitamina K sve dok PT/INR nije bio u terapijskom rasponu (≥2,0).
In both these cases, return the entire pack to the pharmacy.
U oba slučaja vratite cijelo pakiranje u ljekarnu.
In both treatment arms, children aged 6-11 years had a numercally higher rate of confirmed hypoglycaemia than in the other age groups.
U obje terapijske skupine djeca u dobi 6-11 godina imala su brojčano višu stopu potvrđenih hipoglikemija nego u drugim dobnim skupinama.
In both treatment arms, patients with cirrhosis were at a higher risk to experience Grade 3-4 thrombocytopenia compared with non cirrhotic patients.
U obje su ispitivane skupine bolesnici s cirozom imali veći rizik da dobiju trombocitopeniju stupnja 3-4 u usporedbi s bolesnicima bez ciroze.